Henry Low Heart Center, Department of Cardiology, Hartford Hospital, Hartford, CT 06102, USA.
Atherosclerosis. 2011 Dec;219(2):768-73. doi: 10.1016/j.atherosclerosis.2011.09.049. Epub 2011 Oct 4.
We sought to examine the effect of atorvastatin therapy on exercise leg blood flow in healthy middle-aged and older-men and women.
The vasodilatory response to exercise decreases in humans with aging and disease and this reduction may contribute to reduced exercise capacity.
We used a double-blind, randomly assigned, placebo-controlled protocol to assess the effect of atorvastatin treatment on exercising leg hemodynamics. We measured femoral artery blood flow (FBF) using Doppler ultrasound and calculated femoral vascular conductance (FVC) from brachial mean arterial pressure (MAP) before and during single knee-extensor exercise in healthy adults (ages 40-71) before (PRE) and after (POST) 6 months of 80 mg atorvastatin (A: 14 men, 16 women) or placebo (P: 14 men, 22 women) treatment. FBF and FVC were normalized to exercise power output and estimated quadriceps muscle mass.
Atorvastatin reduced LDL cholesterol by approximately 50%, but not in the placebo group (p < 0.01). Atorvastatin also increased exercise FBF from 44.2 ± 19.0 to 51.4 ± 22.0 mL/min/W/kg muscle whereas FBF in the placebo group was unchanged (40.1 ± 16.0 vs. 39.5 ± 16.1) (p < 0.01). FVC also increased with atorvastatin from 0.5 ± 0.2 to 0.6 ± 0.2 mL/min/mmHg/W/kg muscle, but not in the placebo subjects (P: 0.4 ± 0.2 vs. 0.4 ± 0.2) (p < 0.01).
High-dose atorvastatin augments exercising leg hyperemia. Statins may mitigate reductions in the exercise vasodilatory response in humans that are associated with aging and disease.
我们旨在研究阿托伐他汀治疗对健康中年和老年男女运动腿部血流的影响。
随着年龄的增长和疾病的发生，人体运动时的血管舒张反应会减弱，这种减弱可能导致运动能力下降。
我们采用双盲、随机、安慰剂对照方案，评估阿托伐他汀治疗对健康成年人（年龄 40-71 岁）运动腿部血液动力学的影响。我们使用多普勒超声测量股动脉血流（FBF），并在单次股四头肌伸膝运动前后，根据肱动脉平均动脉压（MAP）计算股血管传导率（FVC）。在 6 个月的 80mg 阿托伐他汀（A：14 名男性，16 名女性）或安慰剂（P：14 名男性，22 名女性）治疗前后，分别在健康成年人的腿部进行测量（PRE 和 POST）。将 FBF 和 FVC 标准化为运动功率输出和估计的股四头肌肌肉质量。
阿托伐他汀可使 LDL 胆固醇降低约 50%，但安慰剂组无此变化（p<0.01）。阿托伐他汀还可增加运动时的 FBF，从 44.2±19.0 增加到 51.4±22.0 mL/min/W/kg 肌肉，而安慰剂组的 FBF 则无变化（40.1±16.0 与 39.5±16.1）（p<0.01）。FVC 也随着阿托伐他汀的增加而增加，从 0.5±0.2 增加到 0.6±0.2 mL/min/mmHg/W/kg 肌肉，但安慰剂组则没有变化（P：0.4±0.2 与 0.4±0.2）（p<0.01）。
高剂量阿托伐他汀可增强运动腿部充血。他汀类药物可能减轻与年龄增长和疾病相关的人类运动血管舒张反应的下降。
